Accuray Inc
F:XEJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Accuray Inc
F:XEJ
|
US |
|
R
|
Rolls-Royce Holdings PLC
F:RRU
|
UK |
|
G
|
Goldman Sachs Group Inc
XETRA:GOS
|
US |
|
Dentsu Group Inc
F:DEN0
|
JP |
|
C
|
Compass Minerals International Inc
SWB:CM8
|
US |
|
E
|
Enbridge Inc
F:EN3
|
CA |
|
Atkinsrealis Group Inc
F:LAV0
|
CA |
|
Novartis AG
SIX:NOVN
|
CH |
|
P
|
Pfizer Inc
SIX:PFE
|
US |
|
Enovix Corp
F:6Q81
|
US |
Accuray Inc
Accuray makes radiation therapy systems used to treat cancer and some other medical conditions. Its main products are the CyberKnife and TomoTherapy platforms, along with related software, treatment planning tools, and service contracts. Hospitals and cancer centers buy these systems to deliver highly targeted radiation treatment, often when they want to protect healthy tissue as much as possible during therapy. The company makes money by selling its machines, installing them, and then supporting them over time with service, upgrades, and software. That means its business is a mix of upfront equipment sales and recurring after-sales support. Its customers are medical providers, not patients, so Accuray sits in the middle of the healthcare value chain as a specialized equipment maker rather than a hospital operator or drug company. What makes Accuray different is that it focuses on precision radiation delivery, especially systems designed to aim radiation from many angles with detailed imaging and motion control. In simple terms, it sells tools that help clinicians target tumors more accurately and plan complex treatments. That gives the company a narrower role than broad medical device makers, but one that is tied to a very specific and technical part of cancer care.
Accuray makes radiation therapy systems used to treat cancer and some other medical conditions. Its main products are the CyberKnife and TomoTherapy platforms, along with related software, treatment planning tools, and service contracts. Hospitals and cancer centers buy these systems to deliver highly targeted radiation treatment, often when they want to protect healthy tissue as much as possible during therapy.
The company makes money by selling its machines, installing them, and then supporting them over time with service, upgrades, and software. That means its business is a mix of upfront equipment sales and recurring after-sales support. Its customers are medical providers, not patients, so Accuray sits in the middle of the healthcare value chain as a specialized equipment maker rather than a hospital operator or drug company.
What makes Accuray different is that it focuses on precision radiation delivery, especially systems designed to aim radiation from many angles with detailed imaging and motion control. In simple terms, it sells tools that help clinicians target tumors more accurately and plan complex treatments. That gives the company a narrower role than broad medical device makers, but one that is tied to a very specific and technical part of cancer care.
Guidance withdrawn: Accuray pulled its fiscal 2026 outlook because shipments to customers in the Middle East, North Africa and Pakistan have been delayed indefinitely, while China remains under pressure from geopolitical tensions and tariff uncertainty.
Revenue decline: Third-quarter revenue was about $105 million, up 3% sequentially but down 7% year over year, with product revenue and service revenue both pressured by regional disruptions.
Cost cuts ahead of plan: Management said the transformation program is already delivering about $10 million of improvements and is on track to exceed the original $12 million fiscal 2026 target.
Margins under pressure: Gross margin fell to 24.1% from 27.9% a year ago, hurt by service parts usage, logistics and duties, and tariffs.
Strategic focus: The company is pushing pricing changes, distributor reform, service expansion and new partnerships as part of a broader effort to improve profitability and long-term growth.
Outlook timing: Management said the benefits of the turnaround should become more visible in fiscal 2027 and 2028, even though near-term visibility is limited.
